Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1998-6-3
|
pubmed:abstractText |
The aims of this pilot study were: (i) to compare the efficacy of low-dose clarithromycin (250 mg twice daily) for 1 or 2 weeks; and (ii) to evaluate possible therapeutic advantages in associating the low-dose clarithromycin with an anti-secretory agent or tripotassium dicitrate bismuthate (De Nol; Yamanouchi Pharm, Corugate Milano, Italy). A prospective, randomized, open trial was carried out on consecutive outpatients with dyspeptic symptoms and Helicobacter pylori infection. We enrolled 129 patients in one of the following schedules: (A) De Nol 120 mg q.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks; (B) omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 2 weeks; or (C) omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d. and metronidazole 250 mg q.i.d. for 1 week. Results were evaluated by Per Protocol (PP) and Intention-To-Treat analysis (ITT). Eradication rate was 100% after treatment A, 92.6% after treatment B and 86.5% after treatment C by PP and 83.3, 75.7, and 68.1%, respectively by ITT. Side effects were reported by 16 subjects: 26.6% in group A; 9.1% in group B; and 7.5% in group C; in two cases side effects led to the withdrawal of the treatment. In conclusion, 500 mg clarithromycin per day in association with omeprazole and metronidazole, for 1 week gave comparable results to the same schedule for a 2 week period. The use of clarithromycin with bismuth and metronidazole produced a therapeutic gain compared with both of the anti-secretory schedules, although this was not statistically significant.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0815-9319
|
pubmed:author |
pubmed-author:BattagliaGG,
pubmed-author:BudaAA,
pubmed-author:CassaroMM,
pubmed-author:Dal Bo'NN,
pubmed-author:Di MarioFF,
pubmed-author:KusstatscherSS,
pubmed-author:LeandroGG,
pubmed-author:PilottoAA,
pubmed-author:RuggeMM,
pubmed-author:SalandinSS,
pubmed-author:VianelloFF,
pubmed-author:VigneriSS
|
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
288-93
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9570242-Adult,
pubmed-meshheading:9570242-Aged,
pubmed-meshheading:9570242-Aged, 80 and over,
pubmed-meshheading:9570242-Clarithromycin,
pubmed-meshheading:9570242-Drug Administration Schedule,
pubmed-meshheading:9570242-Female,
pubmed-meshheading:9570242-Helicobacter Infections,
pubmed-meshheading:9570242-Helicobacter pylori,
pubmed-meshheading:9570242-Humans,
pubmed-meshheading:9570242-Male,
pubmed-meshheading:9570242-Middle Aged,
pubmed-meshheading:9570242-Pilot Projects,
pubmed-meshheading:9570242-Treatment Outcome
|
pubmed:year |
1998
|
pubmed:articleTitle |
Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks?
|
pubmed:affiliation |
Istituto di Medicina Interna, Cattedra Malattie Apparato digerente, Università degli Studi di Padova, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|